Amicus Therapeutics Reports FY 2025 Financial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy FOLD?
Source: seekingalpha
- Strong Financial Performance: Amicus Therapeutics reported a FY 2025 non-GAAP EPS of $0.31, indicating a continued improvement in profitability and reflecting robust growth in its core business operations.
- Significant Revenue Growth: The company achieved total revenues of $634 million, marking a substantial increase from the previous year, which underscores the growing acceptance and sales capability of its products in the rare disease market, further solidifying its market position.
- Improved Cash Flow: As of December 31, 2025, Amicus's cash, cash equivalents, and marketable securities rose to $293.5 million, up from $249.9 million in 2024, demonstrating effective cash management and liquidity enhancement.
- Acquisition Interest: BioMarin Pharmaceuticals plans to acquire Amicus for $4.8 billion, reflecting market recognition of Amicus's growth potential and potentially providing stronger resource support and market expansion opportunities for the company.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy FOLD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on FOLD
Wall Street analysts forecast FOLD stock price to rise
9 Analyst Rating
2 Buy
7 Hold
0 Sell
Hold
Current: 14.350
Low
12.00
Averages
14.79
High
19.00
Current: 14.350
Low
12.00
Averages
14.79
High
19.00
About FOLD
Amicus Therapeutics, Inc. is a global biotechnology company focused on discovering, developing and delivering medicines for people living with rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a two-component treatment for adults living with late-onset Pompe disease. As an orally miglustat monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice cell-based amenability assay. Pombiliti + Opfolda consists of an engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance cellular uptake, administered intravenously in combination with orally administered miglustat. In addition, clinical studies are ongoing in pediatric patients for both the LOPD and IOPD populations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Amicus Therapeutics Reports FY 2025 Financial Results
- Strong Financial Performance: Amicus Therapeutics reported a FY 2025 non-GAAP EPS of $0.31, indicating a continued improvement in profitability and reflecting robust growth in its core business operations.
- Significant Revenue Growth: The company achieved total revenues of $634 million, marking a substantial increase from the previous year, which underscores the growing acceptance and sales capability of its products in the rare disease market, further solidifying its market position.
- Improved Cash Flow: As of December 31, 2025, Amicus's cash, cash equivalents, and marketable securities rose to $293.5 million, up from $249.9 million in 2024, demonstrating effective cash management and liquidity enhancement.
- Acquisition Interest: BioMarin Pharmaceuticals plans to acquire Amicus for $4.8 billion, reflecting market recognition of Amicus's growth potential and potentially providing stronger resource support and market expansion opportunities for the company.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating RAPT Therapeutics, Inc.'s sale to GSK plc for $58.00 per share, raising concerns about potential violations of shareholder rights and encouraging shareholders to understand their options.
- Merger Transaction Review: The merger between Contango ORE, Inc. and Dolly Varden Silver Corporation will result in Contango shareholders owning approximately 50% of the combined entity, prompting Halper Sadeh LLC to assess whether this transaction serves the best interests of shareholders.
- Shareholder Equity Protection: Tamboran Resources Corporation's merger with Falcon Oil & Gas Ltd. will allow Tamboran shareholders to hold 73.2% of the combined company, with Halper Sadeh LLC urging shareholders to be aware of potential equity losses.
- Legal Support Services: Amicus Therapeutics, Inc. is being sold to BioMarin Pharmaceutical Inc. for $14.50 per share, and Halper Sadeh LLC offers no-cost legal consultations to assist shareholders in protecting their rights.
See More
Monteverde Law Firm Investigates RAPT and Others for Shareholder Recovery
- Shareholder Recovery Investigation: Monteverde & Associates is investigating RAPT Therapeutics, Inc.'s sale to GSK plc, with RAPT shareholders expected to receive $58.00 per share in cash, which could significantly enhance shareholder returns and bolster investor confidence.
- Amicus Transaction Update: In the proposed sale of Amicus Therapeutics, Inc. to BioMarin Pharmaceutical Inc., Amicus shareholders are anticipated to receive $14.50 per share in cash, with a shareholder vote scheduled for March 3, 2026, potentially impacting the company's future market performance.
- Merger Voting Arrangement: Tamboran Resources Corporation's merger with Falcon Oil & Gas Ltd. will result in Tamboran shareholders owning 73.2% of the combined entity, with a shareholder vote set for March 4, 2026, indicating the company's strategic positioning in industry consolidation.
- Contango Merger Details: The merger between Contango Ore, Inc. and Dolly Varden Silver Corporation will allow Contango shareholders to own 50% of the combined company, with a shareholder vote scheduled for March 17, 2026, which may present new growth opportunities for shareholders.
See More
Halper Sadeh LLC Investigates Multiple Companies for Potential Violations
- Investigation Focus: Halper Sadeh LLC is investigating Janus Henderson Group plc, Amicus Therapeutics, Inc., and RAPT Therapeutics, Inc. for potential violations of federal securities laws related to their sales to Trian Fund Management, BioMarin Pharmaceutical, and GSK plc.
- Transaction Details: The cash sale price for Janus Henderson is $49.00 per share, Amicus is $14.50 per share, and RAPT is $58.00 per share, which may not adequately reflect the companies' true values, potentially harming shareholder interests.
- Shareholder Rights Protection: Halper Sadeh LLC may seek to secure increased consideration for shareholders, additional disclosures, and other relief measures to ensure the protection of shareholders' legal rights.
- Legal Service Commitment: The firm operates on a contingency fee basis, meaning shareholders are not responsible for out-of-pocket legal fees, and they encourage affected shareholders to consult for free regarding their legal rights and options.
See More
Warning Signs for Overbought Healthcare Stocks
- Overbought Signals: As of February 2, 2026, three stocks in the healthcare sector are showing overbought signals with RSI values exceeding 70, indicating potential short-term pullback risks that investors should be cautious about.
- Brookdale Senior Living: This company's stock is in an overbought state with an RSI of 80.4, reflecting strong price momentum but also suggesting possible price adjustment risks, prompting investors to monitor market developments closely.
- Amicus Therapeutics Acquisition: Amicus Therapeutics announced its acquisition by BioMarin, with its stock price surging approximately 139% over the past six months to $14.29, while its RSI of 80.4 indicates strong market interest but also warns of potential corrections.
- Mirum Pharmaceuticals Performance: Mirum Pharmaceuticals is also in an overbought condition, and investors should pay attention to its RSI and market performance to assess future investment risks and opportunities.
See More
BioMarin Pharmaceutical Set to Report 2025 Financial Results Soon
- Earnings Report Anticipation: BioMarin is expected to announce its Q4 and full-year 2025 results in the coming weeks, with last year's report released on the third Wednesday of February, prompting investors to mark February 18, 2026, on their calendars for potential updates.
- Voxzogo Sales Outlook: CFO Brian Mueller indicated that Voxzogo is projected to achieve its highest revenue level of the year in Q4, reflecting strong demand for rare disease drugs, which could drive overall performance growth.
- FDA Approval Progress: The FDA has set a PDUFA date of February 28, 2026, for BioMarin's Palynziq in treating adolescents with phenylketonuria, and approval could provide a new revenue stream, enhancing the company's competitive position.
- Market Competition Risks: Despite positive short-term factors, management expresses caution regarding Voxzogo's long-term outlook, acknowledging potential challenges from competitors that could impact market share and revenue expectations.
See More
Amicus Therapeutics Reports FY 2025 Financial Results
- Strong Financial Performance: Amicus Therapeutics reported a FY 2025 non-GAAP EPS of $0.31, indicating a continued improvement in profitability and reflecting robust growth in its core business operations.
- Significant Revenue Growth: The company achieved total revenues of $634 million, marking a substantial increase from the previous year, which underscores the growing acceptance and sales capability of its products in the rare disease market, further solidifying its market position.
- Improved Cash Flow: As of December 31, 2025, Amicus's cash, cash equivalents, and marketable securities rose to $293.5 million, up from $249.9 million in 2024, demonstrating effective cash management and liquidity enhancement.
- Acquisition Interest: BioMarin Pharmaceuticals plans to acquire Amicus for $4.8 billion, reflecting market recognition of Amicus's growth potential and potentially providing stronger resource support and market expansion opportunities for the company.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating RAPT Therapeutics, Inc.'s sale to GSK plc for $58.00 per share, raising concerns about potential violations of shareholder rights and encouraging shareholders to understand their options.
- Merger Transaction Review: The merger between Contango ORE, Inc. and Dolly Varden Silver Corporation will result in Contango shareholders owning approximately 50% of the combined entity, prompting Halper Sadeh LLC to assess whether this transaction serves the best interests of shareholders.
- Shareholder Equity Protection: Tamboran Resources Corporation's merger with Falcon Oil & Gas Ltd. will allow Tamboran shareholders to hold 73.2% of the combined company, with Halper Sadeh LLC urging shareholders to be aware of potential equity losses.
- Legal Support Services: Amicus Therapeutics, Inc. is being sold to BioMarin Pharmaceutical Inc. for $14.50 per share, and Halper Sadeh LLC offers no-cost legal consultations to assist shareholders in protecting their rights.
See More
Monteverde Law Firm Investigates RAPT and Others for Shareholder Recovery
- Shareholder Recovery Investigation: Monteverde & Associates is investigating RAPT Therapeutics, Inc.'s sale to GSK plc, with RAPT shareholders expected to receive $58.00 per share in cash, which could significantly enhance shareholder returns and bolster investor confidence.
- Amicus Transaction Update: In the proposed sale of Amicus Therapeutics, Inc. to BioMarin Pharmaceutical Inc., Amicus shareholders are anticipated to receive $14.50 per share in cash, with a shareholder vote scheduled for March 3, 2026, potentially impacting the company's future market performance.
- Merger Voting Arrangement: Tamboran Resources Corporation's merger with Falcon Oil & Gas Ltd. will result in Tamboran shareholders owning 73.2% of the combined entity, with a shareholder vote set for March 4, 2026, indicating the company's strategic positioning in industry consolidation.
- Contango Merger Details: The merger between Contango Ore, Inc. and Dolly Varden Silver Corporation will allow Contango shareholders to own 50% of the combined company, with a shareholder vote scheduled for March 17, 2026, which may present new growth opportunities for shareholders.
See More
Halper Sadeh LLC Investigates Multiple Companies for Potential Violations
- Investigation Focus: Halper Sadeh LLC is investigating Janus Henderson Group plc, Amicus Therapeutics, Inc., and RAPT Therapeutics, Inc. for potential violations of federal securities laws related to their sales to Trian Fund Management, BioMarin Pharmaceutical, and GSK plc.
- Transaction Details: The cash sale price for Janus Henderson is $49.00 per share, Amicus is $14.50 per share, and RAPT is $58.00 per share, which may not adequately reflect the companies' true values, potentially harming shareholder interests.
- Shareholder Rights Protection: Halper Sadeh LLC may seek to secure increased consideration for shareholders, additional disclosures, and other relief measures to ensure the protection of shareholders' legal rights.
- Legal Service Commitment: The firm operates on a contingency fee basis, meaning shareholders are not responsible for out-of-pocket legal fees, and they encourage affected shareholders to consult for free regarding their legal rights and options.
See More
Warning Signs for Overbought Healthcare Stocks
- Overbought Signals: As of February 2, 2026, three stocks in the healthcare sector are showing overbought signals with RSI values exceeding 70, indicating potential short-term pullback risks that investors should be cautious about.
- Brookdale Senior Living: This company's stock is in an overbought state with an RSI of 80.4, reflecting strong price momentum but also suggesting possible price adjustment risks, prompting investors to monitor market developments closely.
- Amicus Therapeutics Acquisition: Amicus Therapeutics announced its acquisition by BioMarin, with its stock price surging approximately 139% over the past six months to $14.29, while its RSI of 80.4 indicates strong market interest but also warns of potential corrections.
- Mirum Pharmaceuticals Performance: Mirum Pharmaceuticals is also in an overbought condition, and investors should pay attention to its RSI and market performance to assess future investment risks and opportunities.
See More
BioMarin Pharmaceutical Set to Report 2025 Financial Results Soon
- Earnings Report Anticipation: BioMarin is expected to announce its Q4 and full-year 2025 results in the coming weeks, with last year's report released on the third Wednesday of February, prompting investors to mark February 18, 2026, on their calendars for potential updates.
- Voxzogo Sales Outlook: CFO Brian Mueller indicated that Voxzogo is projected to achieve its highest revenue level of the year in Q4, reflecting strong demand for rare disease drugs, which could drive overall performance growth.
- FDA Approval Progress: The FDA has set a PDUFA date of February 28, 2026, for BioMarin's Palynziq in treating adolescents with phenylketonuria, and approval could provide a new revenue stream, enhancing the company's competitive position.
- Market Competition Risks: Despite positive short-term factors, management expresses caution regarding Voxzogo's long-term outlook, acknowledging potential challenges from competitors that could impact market share and revenue expectations.
See More
